The peroxisome proliferators represent an important group of hepatic carcinogens in rodents that act via the nuclear receptor PPARα. The primary role of PPARα in mediating this response had led to the further characterization of potential events downstream that likely enable the carcinogenic response, including increased peroxisomal fatty acid beta oxidation and the modulation of hepatocellular replication and death, either generally or in preneoplastic lesions. A cooperative role of Kupffer cell activation has been proposed to function in the modulation of hepatocellular proliferation in rodent liver by peroxisome proliferators, but data that confirm or refute this proposal are mixed. Presently there is no evidence that links the Kupffer cell activation by peroxisome proliferators directly to the development of liver tumors. There are marked species differences in susceptibility to peroxisomal proliferation, and active investigation concerning the molecular basis of these differences continues.
INTRODUCTION
Peroxisome proliferators are chemical entities that are defined by the ability to produce an adaptive response in animals, typically in liver tissue and specifically in hepatocytes, characterized by changes in cellular morphology, metabolic capacity, proliferation, and survival (Cattley et al., 1998; Cattley, 2003) . The morphological changes typically include an increase in the volume density of peroxisomes, with or without fluctuations in the endoplasmic reticulum and mitochondria. Susceptibility to peroxisomal proliferation is dramatically influenced by species and to a much lesser degree by sex and strain of animal (Reddy et al., 1974; Tanaka et al., 1992; Lake et al., 2000) .
Peroxisomal proliferation was first identified as a morphological change accompanying hepatomegaly in livers of rodents following oral administration of the hypolipidemic drug, clofibrate (Hess et al., 1965) . Subsequent studies identified the enzymes (notably, those of the peroxisomal fatty acid beta oxidation pathway and the microsomal CYP4A family of enzymes) to be increased in expression and activity in livers undergoing peroxisomal proliferation (Lazarow and deDuve, 1976; Gibson et al., 1982) . In the 1970s, several hypolipidemic drugs were observed to increase the incidence of hepatocellular neoplasia following long-term oral administration to rats or mice (Reddy et al., 1980) . This association of peroxisomal proliferation and risk of liver tumors was extended to studies of chronic effects of orally administered phthalate ester plasticizers such as di-(2-ethylhexyl)phthalate (DEHP) and diphenyl ether herbicides such as lactofen (Kluwe et al., 1982; .
An improved understanding of the mechanism of peroxisomal proliferation was initiated by the identification of a group of receptors known as "Peroxisome Proliferator-Activated Receptors" or PPARs (see review by Escher and Wahli, 2000) . The first PPAR was PPARα, which was cloned and identified as a transcription factor that mediated the expression of genes of the peroxisomal fatty acid beta oxidation pathway and that was inducible by peroxisome proliferators in cells (Issemann and Green, 1990; Issemann et al., 1993) . PPARs are members of the steroid-thyroid hormone receptor superfamily, and act as heterodimeric partners with retinoid X receptor at peroxisome proliferator response elements in specific genes by mediating transcription.
Other than PPARα, 2 additional PPAR subtypes (γ and δ/β) were subsequently identified, and their expression patterns and activators suggested that they mediate responses other than peroxisomal proliferation. However, defining the critical and specific role of PPARα in peroxisomal proliferation was facilitated by the development of a PPARα knockout mouse, in which a germline mutation in the PPARα gene prevented expression of the receptor (Lee et al., 1995) .
Mice that are homozygotic for this mutation are viable, but when they are treated with several peroxisome proliferators (clofibrate, WY-14,643, and DEHP) they do not develop the features of peroxisomal proliferation (hepatomegaly, increased peroxisomal volume density, and enzyme induction) seen in wild-type mice that express functional receptor (Lee et al., 1995; Ward et al., 1998) . To date, only one exception has been observed in that treatment of PPARα knockout mice with a very potent combined PPARγ agonist and PPARδ agonist activities (DeLuca et al., 2000) resulted in a minimal increase in liver weights and peroxisomal enzyme induction. In studies to date, the cell proliferation induced by peroxisome proliferators in livers of wild-type mice also has been absent in studies of PPARα knockout mice. Taken together, the available evidence shows that PPARα is critical to induction of peroxisomal proliferation.
Mechanism of Hepatic Carcinogenesis
Peroxisome proliferators in general are not genotoxic (see review by Galloway et al., 2000) . A variety of nongenotoxic receptor ligands are carcinogenic in rodent liver, and the characterization of the role of receptor activation in the development of hepatic tumors is an area of active investigation. In addition to PPARα (activated by peroxisome proliferators), other receptors (Bunger et al., 2003; Kakizaki et al., 2003) implicated in rodent hepatic carcinogenesis include the Aryl Hydrocarbon receptor (activated by dioxin) and the Constitutive Androstane Receptor (activated by phenobarbital).
The availability of PPARα knockout mice has so far enabled one chronic study of a peroxisome proliferator to determine the role of this receptor in hepatic carcinogenesis. This study used the experimental hypolipidemic drug WY-14,643, fed in the diet at 0.1% concentration by weight for 37 weeks (Peters et al., 1997) . In contrast to the robust induction of hepatocellular neoplasia in 100% of wild-type mice fed dietcontaining WY-14,643, PPARα knockout mice had no gross or microscopic evidence of hepatocellular neoplasia. These results clearly implicated the central role of PPARα in the carcinogenic activity of peroxisome proliferators.
Demonstration of the central role of PPARα in the carcinogenic activity of peroxisome proliferators has led to 2 further questions. First, which of the events that are mediated by activation of PPARα is responsible for the inductions of neoplasia? Second, is activation of PPARα only necessary to mediate the induction of hepatic neoplasia, or is it sufficient to mediate the induction of hepatic neoplasia? These questions will be addressed separately.
PPARα Mediation of Procarcinogenic Effects
Several effects of peroxisome proliferators in rodent liver have been hypothesized to mediate the development of neoplasia observed after chronic treatment. These effects were the focus of mechanistic studies of carcinogenesis before the role of PPARα was characterized. The effects hypothesized to mediate the hepatic carcinogenesis caused by peroxisome proliferators include both the induction of peroxisomal fatty acid beta oxidation and the modulation of hepatocellular replication and death, either generally or in preneoplastic lesions specifically.
The induction of peroxisomal fatty acid beta oxidation was the earliest proposed response to be implicated in the mechanism of carcinogenesis by peroxisome proliferators (Yeldandi et al., 2000) . The first step in this fatty acid beta oxidation pathway is mediated by peroxismal acyl CoA oxidase. Peroxisomal acyl CoA oxidase is different from other acyl CoA oxidases in that its activity leads to the production of a molecule of H 2 O 2 for each 2-carbon chain shortening of the fatty acyl CoA. It is the reactivity of H 2 O 2 with cellular macromolecules, particularly genomic DNA that was hypothesized to account for the carcinogeneic activity of peroxisome proliferators. Thus, an indirect mechanism of genotoxicity or mutagenicity was attributed to peroxisome proliferators, which conveniently explained the consistent lack of direct genotoxicity or mutagenicity observed for these chemical entities. There is evidence that elevated production of H 2 O 2 in peroxisomes can escape, under certain conditions, detoxication by peroixosmal catalase (Conway et al., 1988 (Conway et al., , 1989 . However, it is uncertain whether DNA damage occurs or contributes to the formation of genetic alterations in hepatocytes that are causally related to the development of tumors.
The induction of enzymes of peroxisomal fatty acid beta oxidation, including peroxisomal acyl CoA oxidase, by peroxisomal proliferators is mediated by PPARα. Transriptional promoter regions of genes coding for these enzymes have functional PPRE (Tugwood et al., 1992) . Furthermore, the induction of these genes by peroxisomal proliferators is lacking in PPARα knockout mice (Lee et al., 1995) .
The increased cell replication in hepatocytes resulting from treatment of mice and rats with peroxisome proliferators is a complex response. Typically there is an increase of hepatocytes in S-phase reflecting the DNA replication that occurs upon initiation of treatment with peroxisome proliferators and is associated with hepatomegaly (Cattley, 2003) . This initial increase in hepatocyte number has been proposed to increase the number of hepatocytes at risk for neoplastic development by increasing the frequency of certain mutations in the liver.
The development of hepatomegaly due to hyperplasia of hepatocytes occurs soon after initiation of treatment, and the liver stops increasing in size. As treatment continues, the rate of increase in liver weights decreases, as does the replication of hepatocytes. At some doses of potent peroxisome proliferators, the replication of hepatocytes continues at a rate slightly higher than in controls (Marsman et al., 1988 (Marsman et al., , 1992 . This slightly increased rate of hepatocyte replication appears to be balanced by cell loss, probably by apoptosis. This sustained cell replication appears to relate to higher incidence and earlier onset of hepatic tumors in studies of these chemical entities. However, in other studies, the level of replication of hepatocytes may return to that of controls. Furthermore, in at least one study of clofibrate in rats, the frequency of hepatocytes in S-phase decreased to a level below that of controls (Tanaka et al., 1992) . Taken together, investigations of the effects of peroxisome proliferators on hepatocyte proliferation during periods of continuous daily treatment indicate that the sustained cell replication may adjust the rate of tumor induction, but that other responses are likely to be primary to the mechanism of hepatic carcinogenesis.
The genes responsible for the induction of hepatocyte replication, either with respect to the hyperplasia found immediately upon initiation of treatment with all peroxisome proliferators, or the sustained slight increase sometimes observed to follow the induction of hyperplasia, have not been identified. Both phases of increased cell proliferation were prevented in the PPARα knockout mice (Peters et al., 1997) .
While sustained cell proliferation in the livers of mice and rats has been variably observed under continuous treatment conditions, studies that examine this response have been frequently concentrated on nonneoplastic hepatocytes. In a few studies, however, cell proliferation and cell death have been characterized in preneoplastic and neoplastic hepatocytes. In one study, the effects of peroxisome proliferators on preneoplastic foci, formed in rat liver following an initiating single injection of diethylnitrosamine, was characterized (Marsman, 1991) . This study evaluated the foci containing basophilic hepatocytes, which are most similar to the hepatocytes that form the benign and malignant hepatocellular neoplasms (adenomas and carcinomas, respectively) that appear following sustained treatment with peroxisome proliferators. Within these foci, the frequency of hepatocytes in Sphase was above that of hepatocytes in surrounding nonfocus liver in the absence of treatment with peroxisome proliferator. The frequency was further increased by continuous treatment with either of the peroxisome proliferators employed, WY-14,643 or clofibric acid (Marsman, 1991) . These data provide evidence that peroxisome proliferators directly increase 8 CATTLEY TOXICOLOGIC PATHOLOGY hepatocyte replication within preneoplastic foci, and thereby cause the growth of foci and increase the number of preneoplastic hepatocytes at risk for neoplastic development.
A further evaluation of the effects of peroxisome proliferators on hepatocyte replication was extended to the characterization of effects in benign hepatocellular neoplasms (adenomas). This was studied in livers of rats fed diet containing the peroxisome proliferator WY-14,643 for 43 weeks (Miller et al., 2000) . Upon completion of this time period, rats were either maintained on the WY-14,643-containing diet for an additional time period or were placed on a control diet lacking the peroxisome proliferator. Within 2 days of switching to control diet, the serum level of WY-14,643 dropped dramatically. By comparing the hepatocytes within grossly visible adenomas from rats maintained on WY-14,643 and from rats switched to control diet, differences in cell replication and death were detected. Relative to maintenance on WY-14,643-containing diet, switching to control diet resulted in a decrease in mitotic hepatocytes (an indicator of cell replication) and an increase in apoptotic hepatocytes (an indicator of cell death) within the adenomas. The relevance of this finding to the mechanism of carcinogenesis was further supported by the declining frequency of grossly visible neoplasms in livers of rats examined at 5 weeks after the switch to control diet, and the histological features of tumor regression observed in lesions harvested at this time. These results indicate that even upon reaching the stage of benign grossly visible neoplasia, there was still a dependence of hepatocytes within the lesions upon peroxisome proliferator for stimulation of cell replication and survival.
In addition to the potential mechanistic implications of hepatic responses to peroxisome proliferators, some responses have been used to predict the risk of hepatic carcinogenesis in rats and mice under conditions of long-term treatment. Because of the ease of measurement and the sensitivity of rodent liver, the induction of peroxisomal fatty acid beta oxidation and the hepatomegaly representing hyperplasia both have been used as predictive endpoints (see review by Ashby et al., 1994) . In fact, comparison of the dose response for these predictive endpoints has generally led to the view that dose rates associated with more than trivial increases in peroxisomal enzyme activity (>3-fold of controls) and liver weights (>1.5-fold of controls) in the short term are more than likely to result in an increased incidence of hepatocellular neoplasia if treatment at the same rate is extended to near lifetime duration in the same species. There are no instances in which a peroxisome proliferator increased the risk of liver cancer at doses that did not cause the induction of peroxisomal fatty acid beta oxidation and the hepatomegaly representing hyperplasia in the same species, except when evidence of a different mechanism of carcinogenesis has been identified.
Sufficiency of PPARα for Hepatic Carcinogenicity of Peroxisome Proliferators
The question regarding the sufficiency of PPARα in mediating the carcinogenic activity of peroxisome proliferators is still unanswered. As discussed above, expression of PPARα is absolutely necessary for the carcinogenic activity of peroxisome proliferators in rodent liver, based on results observed in PPARα knockout mice. As knockout mice have no evidence of carcinogenicity, hypothesized procarcinogenic effects, or preneoplastic lesions, there is no viable alternative response mechanism to explain the hepatic carcinogenicity of peroxisome proliferators. However, the possibility that some response mechanism distinct from PPARα might cooperate with PPARα activation and downstream events cannot be excluded based on available data. While acknowledging this possibility, it may also be concluded that there is no proposed cooperative mechanism in the carcinogenicity of peroxisome prolifeators that can be supported by available data.
A proposed mechanism for the increased hepatocyte replication observed upon treatment of rodents with peroxisome proliferators has invoked the activation of Kupffer cells and cytokine signaling from Kupffer cells to hepatocytes. Kupffer cells are resident phagocytic cells present along the endothelial cells lining the sinusoids that comprise the microcirculation of the liver. The role of Kupffer cell cytokines in mediating regenerative hepatocyte proliferation (which is distinct from hyperplasia produced by peroxisome proliferators) has been supported by several studies (see reviews by Taub et al., 1999; Diehl, 2000; Fausto, 2000) . Some of the evidence comes from studies comparing liver regeneration following hepatectomy or severe acute necrosis in wild-type and cytokine receptor knockout mice. In mice with homozygous knockout of genes for TNFR-1 (Yamada et al., 1997; Yamada and Fausto, 1998) or IL-6 (Cressman et al., 1996) , regeneration was inhibited. These studies implicated signaling by Kupffer cell cytokines (TNFα and IL-6) in regenerative hepatocyte replication.
There is conflicting evidence that Kupffer cell activation occurs and may be involved in the hepatocyte replication that follows treatment with peroxisome prolfierators. Some studies have shown that Kupffer cell activation, as evidenced by increased phagocytosis (Bojes and Thurman, 1996) and nuclear translocation of NF-κB (Rusyn et al., 1998 ) may occur soon after treatment of rats with peroxisomal proliferation. Attempts to prevent Kupffer cell activation in rats using methyl palmitate, a nonhydrolyzable fatty acid ester (Rose et al., 1997) , and in mice using genetic deletion of NADPH oxidase, an enzyme producing superoxide in activated Kupffer cells (Rusyn et al., 2000) , resulted in inhibition of replicative DNA synthesis in response to the peroxisome proliferator WY-14,643. Treatment of rats with anti-TNFα antibodies was reported to prevent the hepatocyte replication caused upon initiation of treatment with WY-14,643 (Bojes et al., 1997) . These findings suggested that the hepatocyte replication induced by peroxisome proliferators could depend on Kupffer cell cytokine signaling, in cooperation with PPARα.
The evidence for the role of Kupffer cell activation in the hepatocyte replication that follows treatment with peroxisome proliferators is countered by studies of IL-6, TNFα, TNFR-1 and 2 knockout mice. Mice with genetic deletion of the cytokine TNFα had similar induction of hepatocyte replication as that observed in wild-type mice (Lawrence et al., 2001) . Mice with genetic deletion of the TNFR-1 had the same increases in liver weight and replicatve DNA synthesis following treatment with nafenopin (Wallenius et al., 2000) or WY-14,643 (Anderson et al., 2001) . In the case of WY-14,643, the increase in liver weight and replicative Vol. 32(Suppl. 2), 2004 PEROXISOME PROLIFERATORS 9 DNA synthesis was also unaffected by mice with deletion of TNFR-2 or both receptors,TNFR-1 and 2 (Anderson et al., 2001) . Mice with genetic deletion of IL-6 and treated with peroxisome proliferators, either nafenopin (Wallenius et al., 2000) or ciprofibrate (Ledda-Columbano et al., 1998) also had increases in hepatocyte replication similar to wild-type mice. These results are distinctively different from results obtained in the same knockout mouse strains undergoing regenerative hepatocyte replication following hepatectomy or necrosis-inducing chemicals described previously (Cressman et al., 1996; Yamada et al., 1997; Yamada and Fausto, 1998) . Therefore, the results suggest that the hyperplasia induced by peroxisome proliferators is distinct from regenerative cell replication, and that Kupffer cell-derived cytokines TNFα and IL-6 are not part of the mechanism of action of peroxisome proliferators in rodent liver. There is clearly an opportunity for additional studies to evaluate the potential role of Kupffer cell activation and cytokine release in the mechanism of peroxisome proliferatorinduced hyperplasia in rodent liver. Indeed, the general knowledge concerning the mechanism of nuclear hormone receptor-induced cell proliferation is incomplete. Recent studies of estrogen receptor (ER) indicate the certain nongenomic mechanisms that result in activation of the Mitogen-Associated Protein Kinase (MAPK) signaling cascade may explain some cellular responses to ER independent of its transcriptional activity (Wong et al., 2002) . It also has been suggested that PPARα may affect signaling via the p38 MAPK (Roberts, 2002) . If PPARα elicits signaling via MAPK (or a similar) nongenomic mechanism (in addition to its function as a transcription factor), this might lead to further clarification of the role of PPARα and other receptor pathways in hepatocyte replication.
The significance of findings regarding the role of Kupffer cell activation and cytokine release in mediating responses to peroxisome proliferators to the mechanism of hepatic carcinogenesis caused by these chemical entities is uncertain. To date, no putative activity of Kupffer cells has been experimentally linked to the induction of liver tumors by peroxisome proliferators. Therefore, speculation that Kupffer cell activation is involved in the mechanism of carcinogenesis awaits confirmation by definitive studies.
Species Differences in Peroxisomal Proliferation
The characterization of peroxisomal proliferation, as an increase in peroxisomal fatty acid beta oxidation activity and hepatomegaly resulting from hyperplasia, has been based largely upon studies in rats and mice. A variety of studies indicate that other species are either somewhat less responsive (example, hamster) or dramatically less responsive (guinea pig, primate) to the hepatic effects of peroxisome proliferators (Choudhury et al., 2000; Lake et al., 2000) . Recent experiments in nonhuman primates, including cynomolgus monkeys and marmosets, have extended these findings. In cynomolgus monkeys, administration of DEHP, diisononyl phthalate, or clofibrate at significant dose rates (500, 500, and 250 mg/kg/day, respectively) for 14 days had no effect on peroxisomal fatty acid beta oxidation or liver weight (Pugh et al., 2000) . In marmosets, administration of DEHP (500 or 2500 mg/kg/day) for 13 weeks had no effect on peroxisomal fatty acid beta oxidation or liver weight, whereas clofibrate caused a slight increase in effect on peroxisomal fatty acid beta oxidation while having no effect on liver weight (Kurata et al., 1998) . Taken together, these findings suggest that liver of nonhuman primates is considerably less responsive or nonresponsive to peroxisome proliferators as compared to rodent liver.
Some characterization of response to peroxisome proliferators has been enabled by the clinical use of fibrate drugs that are peroxisome proliferators in rodent liver. Various older studies using liver biopsies from patients placed on fibrate drugs have indicated a lack of increase in peroxisomal volume density by subjective (de la Iglesia, 1992; Blumcke et al., 1993) or objective (Hanefeld, 1983; Gariot, 1987) assessment. In a more recent study, the response of human patients with gallstones and elevated low-density lipoproteins given oral fibrate therapy for 8 weeks was evaluated (Roglans et al., 2002) . There were no differences in levels of peroxisomal acyl CoA oxidase mRNA transcripts between groups receiving fenofibrate, bezafibrate, or gemfibrozil as compared to placebo controls. Taken together, these findings suggest that human liver is nonresponsive to peroxisomal proliferation by drugs that are clearly defined as peroxisome proliferators in rodent liver.
Other than studies in mice and rats, only one publication provides an objective assessment of the carcinogenic activity of peroxisomal proliferators (Lake et al., 1993) . In this study, groups of Syrian hamsters were fed diets containing nafenopin or WY-14,643 for 60 weeks. While these diets were carcinogenic in rat liver, no tumors were detected in livers of Syrian hamsters. These findings were considered consistent with the less robust increase in peroxisomal fatty acid beta oxidation in Syrian hamsters, and the lack of (nafenopin) or equivocal (WY-14,643) hyperplasia detected in this species (see Lake et al., 2000) . The lack of carcinogenicity in Syrian hamster further indicated that species-dependent resistance to peroxisomal proliferation might predict a similar resistance to the carcinogenic potential of peroxisome proliferators in species other than mice and rats.
The molecular basis of the species-dependent resistance to peroxisomal proliferation has been attributed to a variety of differences in the activity of PPARα. Some studies have documented the relatively low level of expression in livers of nonresponsive species such as guinea pigs (Choudhury et al., 2000) and humans (Palmer et al., 1998) . Other studies have identified a truncated form of PPARα expressed in human liver that as dominant negative transcriptional activity (Gervois et al., 1999) . Still other studies have documented species-specific differences in the promoter region of specific peroxisomal genes. The best example of this is the comparison of promoter region of the peroxisomal acyl CoA oxidase gene, which appears to have functional response element(s) in the rat but not humans Woodyatt et al., 1999) . The interpretation of available information therefore indicates a variety of potential explanations for the molecular differences defining species-dependent resistance to peroxisomal proliferation.
